Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1698-1704

  Efficace, F ^a   Bottomley, A ^a   Smit, E F ^b   Lianes, P ^c   Legrand, C ^a   Debruyne, C ^a   Schramel, F ^d   Smit, H J ^e   Gaafar, R ^f   Biesma, B ^g   Manegold, C ^h   Coens, C ^a   Giaccone, G ^b   Van Meerbeeck, J ⁱ  

^a EORTC DATA CENTER   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL DE MATARÓ   (Spain)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e RIJNSTATE HOSPITAL   (Netherlands)

^f NATIONAL CANCER INSTITUTE   (Egypt)

^g JEROEN BOSCH HOSPITAL   (Netherlands)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Lung cancer; Prognostic factor; Quality of life; Survival

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DYSPHAGIA; FACTORIAL ANALYSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; UNIVARIATE ANALYSIS; VALIDATION PROCESS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; EUROPE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; QUALITY OF LIFE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 33750603535     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl183     Document Type: Article

References (28)

1. Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol 2005; 6: 937-944.
2. Seidman AD, Portenoy R, Yao TJ et al. Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer 1995; 87: 1316-1322.
3. Chiarion-Sileni V, Del Bianco P, De Salvo GL et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003; 39: 1577-1585.
4. Maisey NR, Norman A, Watson M et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002; 38: 1351-1357.
5. Fang FM, Liu YT, Tang Y et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 2004; 100: 425-432.
6. Efficace F, Therasse P, Piccart M et al. Health-related quality of life parameters as prognostic factors in a non-metastatic breast cancer population. An international multicenter study. J Clin Oncol 2004; 22: 3381-3388.
7. Glare P, Virik K, Jones M et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003; 327: 195.
8. Greenlee RT, Murray T, Bolden S et al. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
9. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183-194.
10. Herndon JE, Fleishman S, Kornblith AB et al. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 1999; 85: 333-340.
11. Montazeri A, Milroy R, Hole D et al. Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 2001; 31: 233-240.
12. Eton DT, Fairclough DL, Cella D et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21: 1536-1543.
13. Van Steen K, Curran D, Kramer J et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Stat Med. 2002; 21: 3865-3884.
14. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
15. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
16. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30A: 635-642.
17. Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 Scoring Manual. 3rd Edition, Brussels, Belgium, EORTC Publications, 2001.
18. Cull A, Sprangers M, Bjordal K et al. EORTC Quality of Life Group Translation Procedure. Brussels, EORTC Publications, 2002.
19. Cox DR. Regression models and life tables. J Royal Stat Soc 1972; 4: 187-220.
20. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14: 1707-1723.
21. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 1992; 11: 2093-2109.
22. Augustin NH, Sauerbrei W, Schumacher M. Incorporating model selection into prognostic factor model predictions. Freiburg Center for Data Analysis and Modeling, Preprint no. 76 (http://www.fdm.uni-freiburg.de/ pub/preprints.php), 2002.
23. Fayers P, Weeden S, Curran D: EORTC QLQ-C30 Reference Values. Brussels, Belgium, EORTC Publications, 1998.
24. Efficace F, Bottomley A, Coens C et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 2006; 42: 42-49.
25. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
26. Langendijk H, Aaronson NK, de Jong JM et al. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000; 55: 19-25.
27. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005; 23: 6865-6872.
28. Brown J, Thorpe H, Napp V et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005; 23: 7417-7427.